Efficacy of 2LPAPI ®, a Micro-Immunotherapy Drug, in Patients with High-Risk Papillomavirus Genital Infection

Abstract

Human papillomaviruses (HPVs) are well known for being linked to the development of cervical\rcancers, most of them being caused by the high-risk (HR) oncogenic genotypes, mainly 16 and 18.\rThe efficacy of 2LPAPI® (Labo’Life), a micro-immunotherapy homeopathic drug, has been evaluated\rin HR-HPV infected women (n = 18), in a private gynecology practice, by comparing them to\ran untreated control group (n = 18). Patients were 20 to 45 years old and had cytology with Atypical\rSquamous Cells of Undetermined Significance (ASCUS) or Low grade Superficial Intra Lesions/\rCervical Intraepithelial Neoplasia Grade I (LSIL/CINI). Patients freely chose to be treated with the\rdrug or not. Those deciding not to take the drug remained untreated and were followed as a control\rgroup. The drug was taken at the regimen of one capsule per day during 6 months. HR-HPV\rand cytology were evaluated at 6 and 12 months. After 12 months, HR-HPV was cleared in 78% of\rthe patients taking the drug versus 44% in those not taking it (p = 0.086). In patients over 25 years,\rHR-HPV clearance in the treated group was significantly higher (81.3%) than in the control group\r(20%) (p = 0.004). The difference in the regression of the lesion grades almost reached statistical\rsignificance (p = 0.053). This follow-up confirms that the micro-immunotherapy drug 2LPAPI® is a\rsafe and effective therapeutic approach to treat HR-HPV cervical lesions in women over 25 years.